ContextVision introduces AI-powered image enhancement for radiography
"With the integration of artificial intelligence (AI), ContextVision takes radiography to new levels with Altumira(TM)," said Anita Tollstadius, CEO of ContextVision. "This shows that our strong focus on R&D towards AI, is paying off."
Altumira(TM) is designed for all digital radiography systems, from plain X-ray to the most advanced angiography systems, and advances ContextVision's present product portfolio of state-of-the-art image enhancement for X-ray. This is the first product from the company combining AI with the proprietary GOP technology to address the challenges regarding durability and high image quality that have been difficult to solve before.
"This new product has been designed for X-ray systems that can be used for both static and dynamic imaging. These combined systems are increasingly being used in healthcare and a growing segment," said Tollstadius.
The new image enhancement platform offers image enhancement with a greater resilience. Using AI, optimal image quality can be achieved even with varying conditions such as different dose exposures and different anatomies for both static and dynamic imaging. This technology provides unique features and great results both in low-dose fluoro sequences and high-quality angiography sequences.
"Our customers can now meet the demanding needs of digital radiography today, by handling all types of variations within and between images and sequences for both plain and dynamic digital radiography," Tollstadius said. "With our next-generation image enhancement, we're bringing great value and confidence to both manufacturers and radiologists, providing them the highest image quality in every exam."
###
About ContextVision
ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision is significantly investing in R&D to develop new applications of the latest artificial intelligence technologies and expanding into the growing digital pathology market. The release of its first product, supporting the diagnosis of prostate cancer, is planned in the near future.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
For more information please visit www.contextvision.com.